Clinical trials: Dysphagia

Gastroesophageal Reflux Disease (GERD)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)

• Completed
• Age: 18 to 85 years
• Phase 4

This study includes patients with sleep disturbances associated with gastroesophageal reflux disease (GERD) and has 3 treatment arms.

Trial name

NCT00628342

Testing

Esomeprazole

Volunteers

600 people

Sponsor

AstraZeneca